ArticleBiomarker research2026
Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations.
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
MicroRNA-based biomarkers hold promise for precision oncology, but standardization and pre-analytical variability remain barriers to clinical use. We performed a technical study to assess how the type of biological material (plasma, serum) and quantification (miRNA-seq, RT-qPCR) method affect microRNA (miRNA) levels. Samples from 202 women – 154 carriers of BRCA1/2 pathogenic variants, from three centers were collected. MiRNAs were quantified using miRNA sequencing (miRNA-seq), a quantitative PCR (qPCR) panel of 182 miRNAs (Qiagen) or targeted qPCR of 13 miRNA associated with BRCA mutations or ovarian cancer. Differential expression and linear regression analyses were used to assess methods concordance and biological material-related differences. Differences of individual miRNA levels between serum and plasma were more pronounced in sequencing than in qPCR. miR-193a-3p, miR-197-3p, miR-877-5p and miR-2110 were detected in significantly higher amounts in serum, while miR-28-5p in plasma, by both sequencing and qPCR. Measurements done by sequencing and qPCR correlated positively and significantly for ~ 75% of investigated miRNA. Finally, strong inter-assay correlation of established qPCR hemolysis marker (based on miR-451a and miR-23a-3p) provided evidence that it can be used also in sequencing data. Differences in absolute and relative miRNA levels in serum and plasma necessitate material-specific test calibration and may impact selection of best miRNA biomarkers for specific scenarios. Concordance in expression levels quantified by miRNA-seq and qPCR is generally good for high-expression miRNAs in both serum and plasma, but a conversion of multi-miRNA tests from serum to plasma is unfeasible without experimental calibration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.